EU/EMA Drug Approvals for HYDROCHLOROTHIAZIDE; IRBESARTAN

Subscribe to access the full database, or Start Trial
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
sanofi-aventis groupe	Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)	irbesartan, hydrochlorothiazide	EMEA/H/C/000783Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	no	no	no	2007-01-18
Sanofi Winthrop Industrie	Karvezide	irbesartan, hydrochlorothiazide	EMEA/H/C/000221Treatment of essential hypertension.This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	no	no	no	1998-10-16
Sanofi Winthrop Industrie	CoAprovel	irbesartan, hydrochlorothiazide	EMEA/H/C/000222Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	no	no	no	1998-10-14
Krka, d.d., Novo mesto	Ifirmacombi	irbesartan, hydrochlorothiazide	EMEA/H/C/002302Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	yes	no	no	2011-03-04
Teva B.V.	Irbesartan/Hydrochlorothiazide Teva	irbesartan, hydrochlorothiazide	EMEA/H/C/001112Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	yes	no	no	2009-11-26
Bristol-Myers Squibb Pharma EEIG	Irbesartan Hydrochlorothiazide BMS	irbesartan, hydrochlorothiazide	EMEA/H/C/000784Treatment of essential hypertension.This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).	Withdrawn	no	no	no	2007-01-19
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

Last updated: April 24, 2026

What is the product and how is it positioned commercially?

Hydrochlorothiazide (HCTZ) + irbesartan is a fixed-dose combination antihypertensive used for treatment of hypertension. The market structure follows standard generic entry dynamics: brand-led adoption in early years, then share shift to generics once patents and exclusivities lapse, with pricing compressed accordingly.

Core commercial posture

Therapeutic category: Renin-angiotensin system inhibitor (irbesartan) plus thiazide diuretic (HCTZ).
Demand driver: Chronic hypertension prevalence and long persistence on therapy.
Competitive driver: Generic substitution and payor formulary placement.
Regulatory driver: Combination coverage persists through product-specific exclusivities and brand labeling; generics expand through ANDA and national registrations.

How do market dynamics shape demand for HCTZ/irbesartan?

1) Chronic use supports stable baseline volume

Hypertension therapy is long-duration, so volume is typically less cyclical than acute-care drugs. For fixed-dose combinations, persistence tends to depend on:

symptom control and tolerability (electrolyte and renal monitoring requirements),
guideline alignment for ARB plus diuretic strategies,
switching costs and formulary restrictions.

2) Fixed-dose combinations face two competing forces

Adoption friction: Not all patients tolerate or require two agents at once; prescribers may start with monotherapy then titrate.
Adherence benefit: Once a combination is tolerated, adherence can improve versus separate dosing. That increases likelihood of refill continuity.

3) Generic penetration is the dominant pricing and margin variable

After exclusivity gaps, pricing falls and volume can shift based on:

lowest-cost generic launches,
pharmacy benefit manager (PBM) contracting,
state or national substitution rules.

Given the age of the underlying ARB and the generic maturity of many ARBs, the long-run market trajectory is usually characterized by:

a sharp brand revenue decline after generic entry,
slower erosion for the combination segment if combination-specific launches lag some monotherapies,
eventual normalization of retail and payer prices into a multi-generic competitive equilibrium.

What does the historical financial trajectory look like at the class and molecule level?

Because HCTZ/irbesartan is a combination product, financial trajectory depends on (i) the irbesartan commercial lifecycle and (ii) the combination product’s patent and exclusivity posture in each major market. Globally, irbesartan has already transitioned through:

initial brand growth,
peak period before generic erosion,
multi-year revenue decline as generics entered.

A proxy for this lifecycle pattern is visible in the broader ARB market and in aggregated payer and sales reporting for irbesartan-containing products. Irbesartan sales and market share have historically been tracked and reported by multiple industry data providers; the direction is consistent: peak, then sustained erosion with generic penetration across large markets.

How does competitive structure affect pricing for HCTZ/irbesartan?

Competitive set

HCTZ/irbesartan competes against:

Other ARB/HCTZ fixed-dose combinations (class substitution).
ARB plus HCTZ given as separate tablets (prescriber and payer channel flexibility).
Other diuretic + antihypertensive fixed-dose combinations (e.g., ARB/CCB, ACEi/diuretic).

Price pressure mechanics

After generic entry, rebates drive net price toward contracted benchmarks.
PBM preferred status determines the effective market price more than list price.
Multiple generics reduce pricing power; market share becomes contestable by contract rather than brand performance.

Product-specific constraints

Combination products can face tighter formulary scrutiny because:

pill burden and titration flexibility,
electrolyte monitoring requirements (HCTZ),
fixed-dose mismatch when patients need dose adjustment of only one component.

That constraint can slow uptake in some formularies even after generic availability.

What is the regulatory and labeling anchor for clinical use?

The product is positioned in standard hypertension treatment frameworks, using:

irbesartan’s RAAS blockade,
HCTZ’s diuretic effect.

In the US product labeling for irbesartan-containing regimens, the combination is framed for hypertension control. Clinical expectations include reductions in blood pressure and standard antihypertensive monitoring considerations, including renal function and electrolyte status for thiazide-containing regimens. (U.S. FDA labeling for irbesartan and combination products is the anchor for claims and contraindications.) [1]

What does patent and exclusivity structure imply for market timing?

For a mature ARB, the market timing typically looks like this:

early years: brand exclusivity and payer contracting that supports penetration,
mid-to-late years: combination patent cliffs and formulation/marketing exclusivity expiration,
later years: generic entry and expanding competitive set.

For business planning, the combination’s financial trajectory depends on whether combination-specific exclusivities (not just molecule-level exclusivities) remained in force in key markets. Once combination-specific protection ends, generics can enter with multiple strengths, causing pricing compression.

How should financial trajectory be modeled (revenue, unit sales, and margin)?

A realistic financial model for HCTZ/irbesartan post-brand peak typically uses three phases:

Phase 1: Brand-led growth to peak

Unit growth supported by physician awareness and formulary coverage.
Revenue growth outpaces general market because of differentiation by brand availability and patient onboarding.

Phase 2: Generic erosion begins

Net price falls when AB-rated generics enter and PBM preferred status shifts.
Volume may hold initially if brand share does not collapse immediately, then shifts to generics as substitution accelerates.

Phase 3: Mature generic equilibrium

Multiple generics stabilize into a low-price, high-volume environment.
Revenue tracks population and hypertension treatment rates more than differentiation.
Margins compress; differentiation becomes contract-based, not product-based.

This structure is consistent with how ARB-based combination products usually evolve once patent estates expire in major geographies.

Market-specific dynamics that affect financial outcomes

Major geographies typically diverge on:

speed of generic approval and launch,
formulary coverage cycles,
pricing regulation or strong rebate governance,
pharmacy substitution rates.

United States

Generic substitution and PBM contracting drive net price compression.
Combination tablets tend to retain volume if payers prefer fixed-dose regimens, but price pressure is persistent once multiple generics exist.

Europe

Price competition and tendering dynamics can compress pricing faster once multiple generics appear.
Uptake depends on guideline adherence and reimbursement design by country.

Other markets

Tender-driven procurement and local generic launch calendars determine timing.
Net price dynamics can remain uneven due to varying enforcement and supply.

Key financial metrics to monitor for HCTZ/irbesartan

For investment and R&D strategy, the most decision-relevant metrics are:

Net price trend (not list): measures payer contracting and rebate erosion.
Unit share shift: reveals whether the combination retains share versus monotherapy or rival combinations.
Strength-level distribution: fixed-dose combinations compete by strength availability.
Formulary presence: whether the combination remains preferred versus monotherapies or other fixed-dose options.
Stock pipeline and launch cadence: multiple generic entrants can cause abrupt price adjustments.

What is the practical outlook for future revenue trajectory?

For an established ARB + thiazide combination, the forward trajectory generally trends toward:

flat-to-slow revenue growth in volume terms (population and hypertension treatment rate),
continued margin compression (net price pressure),
occasional step-changes from new generic launches, contract cycles, or discontinuations.

Since the underlying clinical value is mature and the molecule is widely available in generic forms, the combination’s financial performance usually depends on contractual positioning rather than therapeutic breakthroughs.

Key Takeaways

HCTZ/irbesartan is a mature fixed-dose hypertension regimen with a commercial path dominated by generic entry and PBM contracting.
The long-run financial trajectory for such combinations typically follows a brand peak, revenue decline on generic erosion, then stabilization at low net pricing with volume driven by adherence and formulary preference.
For decision-making, track net price, unit share, strength-level demand, and formulary preference shifts, since these explain most post-peak revenue movement.

FAQs

1) Is HCTZ/irbesartan primarily positioned as first-line therapy or add-on?

It is used within hypertension treatment pathways where combination therapy is appropriate, often as add-on or when monotherapy does not achieve control. The fixed-dose format supports adherence after titration decisions. [1]

2) What usually drives revenue changes after generic entry?

Net price declines due to PBM contracting and pharmacy substitution, with volume shifts that can lag price erosion. The largest impact typically comes from the timing and number of generic launches.

3) Does the combination retain any differentiation versus using irbesartan plus HCTZ separately?

Yes, fixed dosing can improve adherence and reduce pill burden, which can help maintain share where payers prefer combination regimens. The effect is usually smaller than pricing pressure once multiple generics exist.

4) Which risk factors can influence market demand?

Side-effect monitoring needs related to thiazide (electrolytes, renal function) and contraindications or tolerability constraints can limit uptake for some patients, affecting prescriber switching patterns.

5) What signals indicate that price erosion will accelerate?

A new wave of AB-rated generic launches in multiple strengths and subsequent PBM contract renegotiations usually lead to step-downs in net pricing and faster share migration to lower-cost SKUs.

References

[1] U.S. Food and Drug Administration. (n.d.). Irbesartan and hydrochlorothiazide prescribing information and labeling. FDA access data (labeling for irbesartan-containing products). https://www.accessdata.fda.gov/

US Patents:	0
Tradenames:	2
Applicants:	16
NDAs:	16
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	16
DailyMed Link:	HYDROCHLOROTHIAZIDE; IRBESARTAN at DailyMed

Sponsor	Phase
Shanghai Jiao Tong University School of Medicine	NA
Vital Strategies	NA
Damanhour University	N/A

Applicant	Application No.	Strength	Dosage Form
⤷ Start Trial	⤷ Start Trial	12.5MG;300MG	TABLET;ORAL
⤷ Start Trial	⤷ Start Trial	12.5MG;150MG	TABLET;ORAL
⤷ Start Trial	⤷ Start Trial	25MG;300MG	TABLET; ORAL

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVALIDE	Tablets	hydrochlorothiazide; irbesartan	300 mg/25 mg	020758	1	2006-06-06
AVALIDE	Tablets	hydrochlorothiazide; irbesartan	150 mg/12.5 mg and 300 mg/12.5 mg	020758	1	2004-11-10

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Atlas Pharms Llc	IRBESARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	203036-003	Jan 15, 2016		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hisun Pharm Hangzhou	IRBESARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	207896-002	Oct 14, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin Ltd	IRBESARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	201524-001	Feb 27, 2013		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Macleods Pharms Ltd	IRBESARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	202414-002	Sep 27, 2012	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin Ltd	IRBESARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	201524-002	Feb 27, 2013		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	IRBESARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	090351-003	Jun 8, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Summary for HYDROCHLOROTHIAZIDE; IRBESARTAN

Recent Clinical Trials for HYDROCHLOROTHIAZIDE; IRBESARTAN

Generic filers with tentative approvals for HYDROCHLOROTHIAZIDE; IRBESARTAN

Pharmacology for HYDROCHLOROTHIAZIDE; IRBESARTAN

Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE; IRBESARTAN

Paragraph IV (Patent) Challenges for HYDROCHLOROTHIAZIDE; IRBESARTAN